

Resource Summary Report

Generated by [RRID](#) on Sep 6, 2026

Ms CD8a BUV496 53-6.7 50ug

RRID:AB_2874242

Type: Antibody

Proper Citation

BD Biosciences Cat# 750024, RRID:AB_2874242

Antibody Information

URL: http://antibodyregistry.org/AB_2874242

Proper Citation: BD Biosciences Cat# 750024, RRID:AB_2874242

Target Antigen: CD8a

Host Organism: rat

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: Ms CD8a BUV496 53-6.7 50ug

Description: This monoclonal targets CD8a

Target Organism: mouse

Clone ID: 53-6.7

Antibody ID: AB_2874242

Vendor: BD Biosciences

Catalog Number: 750024

Record Creation Time: 20231110T031857+0000

Record Last Update: 20260829T193233+0000

Ratings and Alerts

No rating or validation information has been found for Ms CD8a BUV496 53-6.7 50ug.

No alerts have been found for Ms CD8a BUV496 53-6.7 50ug.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 11 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Zhang Y, et al. (2026) Preoperative exercise induces anti-tumor Kupffer cells to prevent surgical stress-promoted colorectal cancer liver metastasis. Cell reports. Medicine, 7(2), 102589.

Rennen S, et al. (2025) Lipid nanoparticles as a tool to dissect dendritic cell maturation pathways. Cell reports, 44(8), 116150.

Benjamin JS, et al. (2025) 23ME-01473, an Fc Effector-Enhanced Anti-ULBP6/2/5 Antibody, Restores NK Cell-Mediated Antitumor Immunity through NKG2D and FcγRIIIa Activation. Cancer research communications, 5(3), 476.

Scott MC, et al. (2025) Deep profiling deconstructs features associated with memory CD8+ T cell tissue residence. Immunity, 58(1), 162.

van der Heide V, et al. (2025) Prolonged but finite antigen presentation promotes reversible defects of "helpless" memory CD8+ T cells. Immunity, 58(7), 1742.

Song NJ, et al. (2025) Tumor-associated NK Cells Regulate Distinct CD8+ T-cell Differentiation Program in Cancer and Contribute to Resistance against Immune Checkpoint Blockers. Cancer discovery, 15(9), 1835.

Alzeeb G, et al. (2024) Efficacy of novel allogeneic cancer cells vaccine to treat colorectal cancer. Frontiers in oncology, 14, 1427428.

Calì B, et al. (2024) Coagulation factor X promotes resistance to androgen-deprivation therapy in prostate cancer. Cancer cell, 42(10), 1676.

Bancaro N, et al. (2023) Apolipoprotein E induces pathogenic senescent-like myeloid cells in prostate cancer. Cancer cell, 41(3), 602.

Wanhainen KM, et al. (2022) P2RX7 Enhances Tumor Control by CD8+ T Cells in Adoptive Cell Therapy. Cancer immunology research, 10(7), 871.

Denis M, et al. (2022) Impact of mouse model tumor implantation site on acquired resistance to anti-PD-1 immune checkpoint therapy. Frontiers in immunology, 13, 1011943.